Protocol: SWOG – S1912CD
Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!
- Patients must have a diagnosis of a metastatic solid tumor or a hematologic malignancy and must receive anti-cancer treatment per the timing described in Section 5.2a (i.e. chemotherapy, hormonal therapy, targeted therapy, biologic therapy, immune therapy, bone marrow transplant). Patients with indolent hematologic diseases undergoing observation alone are not eligible.
- Patients with recurrent solid tumors will be allowed as long as 1) this is the first presentation of metastatic disease and 2) the diagnosis of the metastasis is at least
180 days (6 months) after the diagnosis date of the previous earlier stage cancer.
- Patients with a history of secondary malignancy are allowed as long as they were not diagnosed within the previous 24 months, are not on active therapy, and are
disease-free. Patients with adequately treated basal cell or squamous cell skin cancer, and in situ cervical cancer at any point prior to enrollment are eligible.
- Patients who have started anti-cancer treatment for the current diagnosis must have started within 60 days prior to registration.
- Patients who are planning to start anti-cancer treatment for the current diagnosis must start within (≤) 30 days after registration.
- Patients may not be enrolled in hospice care at the time of registration.
- Patients must be at least 18 years of age.
- Patients must have a Zubrod performance status of 0-2.
- Patients must provide their full name, primary address in the U.S., birth date and social security number at registration for the purposes of accessing credit report
data. (This may be obtained directly from the patient, study questionnaires, or the medical record.)
- Spouse caregivers must be willing to participate in the trial.
- Spouse caregivers must be legally married, or file their tax returns as married filing jointly.*
- Spouse caregivers must be living in the same household with the eligible patient enrolling in this trial.